Severe Neutropenia and Thrombocytopenia Associated with Infliximab
Authors: Francesc Vidal, Ramn Fontova, Cristbal Richart
Journal: Annals of Internal Medicine (2003)

Letters5 August 2003Severe Neutropenia and Thrombocytopenia Associated with InfliximabFrancesc Vidal, MD, PhD, Ramn Fontova, MD, PhD, and Cristbal Richart, MD, PhDFrancesc Vidal, MD, PhDHospital Universitari Joan XXIII, Universitat Rovira i Virgili; 43007 Tarragona, Spain (Vidal, Fontova, Richart), Ramn Fontova, MD, PhDHospital Universitari Joan XXIII, Universitat Rovira i Virgili; 43007 Tarragona, Spain (Vidal, Fontova, Richart), and Cristbal Richart, MD, PhDHospital Universitari Joan XXIII, Universitat Rovira i Virgili; 43007 Tarragona, Spain (Vidal, Fontova, Richart)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-139-3-200308050-00021-w4 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: Infliximab, a monoclonal antitumor necrosis factor (TNF)- antibody, has recently been approved for treatment of rheumatoid arthritis (1, 2). To date, therapy with this drug has been associated with few adverse events (3-5).Objective: To describe a patient who developed severe neutropenia and thrombocytopenia after administration of infliximab.Case Report: A 60-year-old woman had developed rheumatoid arthritis in her forties. She had received many drugs, including nonsteroidal anti-inflammatory drugs, steroids, chloroquine, cyclophosphamide, and methotrexate (up to 15 mg/wk), with good hematologic tolerance but poor clinical results. The disease progressed markedly, and by the beginning of 2001, ...References1. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, . Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-602. [PMID: 11096166] CrossrefMedlineGoogle Scholar2. Klippel JH. Biologic therapy for rheumatoid arthritis [Editorial]. N Engl J Med. 2000;343:1640-1. [PMID: 11096174] CrossrefMedlineGoogle Scholar3. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs. 2000;59:1341-59. [PMID: 10882166] CrossrefMedlineGoogle Scholar4. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, . Tuberculosis associated with infliximab, a tumor necrosis factor -neutralizing agent. N Engl J Med. 2001;345:1098-104. [PMID: 11596589] CrossrefMedlineGoogle Scholar5. Nunez Martinez O, Ripoll Noiseux C, Carneros Martin JA, Gonzalez Lara V, Gregorio Maranon HG. Reactivation tuberculosis in a patient with anti-TNF- treatment [Letter]. Am J Gastroenterol. 2001;96:1665-6. [PMID: 11374737] CrossrefMedlineGoogle Scholar6. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001;96:722-9. [PMID: 11280541] CrossrefMedlineGoogle Scholar7. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, . A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586-93. [PMID: 11096165] CrossrefMedlineGoogle Scholar8. Keystone EC. Tumor necrosis factor- blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27:427-43. [PMID: 11396102] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Hospital Universitari Joan XXIII, Universitat Rovira i Virgili; 43007 Tarragona, Spain (Vidal, Fontova, Richart) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byRheumatoid arthritis: current therapeutics compendiumCurrent Perspectives on the Role of TNF in Hematopoiesis Using Mice With Humanization of TNF/LT SystemThe Blood in RheumatologyBiologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARDCombination of infliximab with thiopurines significantly reduces white cell and neutrophil counts in inflammatory bowel disease patientsSevere Thrombocytopenia Induced by First Infliximab Administration for Rheumatoid ArthritisNeutropenia in the Elderly: A Rheumatology PerspectiveEtanerceptInfliximabAdalimumabInfliximabBiological therapy and dentistry: a review paperSegurança do uso de terapias biológicas para o tratamento de artrite reumatoide e espondiloartritesSafe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritidesEtanercept-Associated Transient Bone Marrow Aplasia: A Review of the Literature and Pathogenetic MechanismsÉvaluation du rapport bénéfice-risque de la suspension des anti-TNF alpha en chirurgie oraleAntiphospholipid antibodies during 6-month treatment with infliximab: A preliminary reportUnexpected Hematologic Effects of Biotherapeutics in Nonclinical Species and in HumansPerioperative Management of the Neutropenic Rheumatologic PatientA Case of Immune Thrombocytopenic Purpura Associated with Preexisting Ulcerative Colitis Treated with Colectomy and SplenectomySevere adalimumab-induced thrombocytopenia in a patient with Crohn's diseaseDifferential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patientsPerioperative Management of Rheumatoid MedicationsReview article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapySafety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritisAnti-TNF therapy induced immune neutropenia in Crohns disease- report of 2 cases and review of literatureDrug-induced platelet disordersSevere agranulocytosis following first infliximab infusion in Crohn's diseaseAn inconspicuous insect bite as the cause of sepsis in a patient treated with infliximab due to rheumatoid arthritisEosinophilia during Psoriasis Treatment with TNF AntagonistsInfliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years' drug survivalA decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel diseaseTransient and reversible thrombocytopenia in a psoriatic patient treated with etanerceptAdverse Drug Reactions Affecting Blood CellsGLUCOCORTICOIDS AND DISEASE – MODIFYING ANTIRHEUMATIC DRUGSImmune Thrombocytopenia in Patients with Connective Tissue Disorders and the Antiphospholipid Antibody SyndromeDrug-induced immune thrombocytopenia: pathogenesis, diagnosis, and managementThrombocytopenia associated with the use of anti–tumor necrosis factor–α agents for psoriasisAddition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis following Allogeneic Peripheral Blood Cell TransplantationNeutropénie et thrombopénie chez un malade traité par étanercept pour un psoriasisGuidelines of care for the management of psoriasis and psoriatic arthritisEs necesario el control de la psoriasis a largo plazoFrom the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasisInfliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatmentSevere neutrophilia induced by infliximab for psoriasisAntitumor necrosis factor-induced neutropenia: a case report with double positive rechallengesComplications and Adverse Reactions in the Use of Newer Biologic AgentsReversible T-large granular lymphocyte expansion and neutropenia associated with adalimumab therapyDemonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitisT-cell Lymphopenia Associated with Infliximab and CyclophosphamideCan We Alter The Natural History Of Crohn Disease In Children?Update on the British Society for Rheumatology guidelines for prescribing TNF blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)Drugs that act on the immune system: cytokines and monoclonal antibodiesEtanercept: Questions and Answers 5 August 2003Volume 139, Issue 3Page: W-63KeywordsBlood countsDrug therapyDrugsFeversGranulocytesMacrophagesMethotrexateNeutropeniaPatientsRheumatoid arthritis ePublished: 5 August 2003 Issue Published: 5 August 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...